Opportunities to Boost Naloxone Awareness among People who Misuse Opioid Analgesics who have not used Illegal Opioids

Abstract

Background

Increasing naloxone awareness and carrying among individuals who misuse opioid analgesic medications (OAs) could reduce opioid overdose mortality.

Methods

Self-report surveys were completed by 322 adults receiving residential addiction treatment who misused OAs in the past year. Descriptive analyses and prevalence ratios (using Poisson generalized estimating equations) examined whether illegal opioid (e.g., heroin) initiation was associated with naloxone awareness.

Results

Among this sample of participants who misused OAs, naloxone awareness was lowest among those who never used illegal opioids (26%) and highest among those who transitioned from OAs to illegal opioid use over time (83%). Naloxone awareness remained higher among participants who had used illegal opioids after adjustment for sociodemographic and substance use characteristics. Those who used OAs before initiating illegal opioids were 2.3-fold (95% CI: 1.5–3.3) more likely to have naloxone awareness than those who had only misused OAs after adjustment. Half of participants who had only used OAs had experienced an overdose, 75% had witnessed an overdose, and 61% were prescribed OAs to treat pain in the past 6 months.

Conclusions

Implementing overdose education and naloxone distribution programs during addiction treatment could bolster naloxone awareness among people who misuse OAs but who have not used illegal opioids.

Keywords

Naloxone opioids heroin overdose harm reduction addiction treatment services

Get full access to this article

View all access options for this article.

References

Fairbairn

, Coffin

, Walley

AY.

Naloxone for heroin, prescription opioid, and illicitly made fentanyl overdoses: Challenges and innovations responding to a dynamic epidemic. Int J Drug Policy. 2017;46:172–179.

Tobin

, Clyde

, Davey-Rothwell

, Latkin

Awareness and access to naloxone necessary but not sufficient: Examining gaps in the naloxone cascade. Int J Drug Policy. 2018;59:94–97.

Dowell

, Haegerich

, Chou

CDC guideline for prescribing opioids for chronic pain – United States, 2016. MMWR Recomm Rep. 2016;65(1):1–49.

Behar

, Bagnulo

, Coffin

PO.

Acceptability and feasibility of naloxone prescribing in primary care settings: a systematic review. Prev Med. 2018;114:79–87.

Dunn

, Barrett

, Yepez-Laubach

, . Brief Opioid Overdose Knowledge (BOOK): a questionnaire to assess overdose knowledge in individuals who use illicit or prescribed opioids. J Addict Med. 2016;10(5):314–323.

Huhn

, Garcia-Romeu

, Dunn

KE.

Opioid overdose education for individuals prescribed opioids for pain management: randomized comparison of two computer-based interventions. Front Psychiatry. 2018;9:34.

Bohnert

ASB

, Valenstein

, Bair

, . Association between opioid prescribing patterns and opioid overdose-related deaths. JAMA. 2011;305(13):1315–1321.

Dunn

, Saunders

, Rutter

, . Opioid prescriptions for chronic pain and overdose: a cohort study. Ann Intern Med. 2010;152(2):85–92.

Muhuri

, Gfroerer

, Davies

Associations of nonmedical pain reliever use and initiation of heroin use in the United States. CBHSQ Data Review. 2013. https://www.samhsa.gov/data/sites/default/files/DR006/DR006/nonmedical-pain-reliever-use-2013.htm.

10.

Fernandez

, Bush

, Bonar

, Blow

, Walton

, Bohnert

Alcohol and drug overdose and the influence of pain conditions in an addiction treatment sample. J Addict Med. 2019;13(1):61–68.

11.

Gicquelais

, Mezuk

, Foxman

, Thomas

, Bohnert

Justice involvement patterns, overdose experiences, and naloxone knowledge among men and women in criminal justice diversion addiction treatment. Harm Reduct J. 2019;16(1):46.

12.

Butler

, Budman

, Fernandez

, . Development and validation of the current opioid misuse measure. Pain. 2007;130(1–2):144–156.

13.

Price

, Ilgen

, Bohnert

Prevalence and correlates of nonmedical use of prescription opioids in patients seen in a residential drug and alcohol treatment program. J Subst Abuse Treat. 2011;41(2):208–214.

14.

Mars

, Ondocsin

, Ciccarone

Sold as heroin: perceptions and use of an evolving drug in baltimore, MD. J Psychoactive Drugs. 2018;50(2):167–176.

15.

Zou

A modified poisson regression approach to prospective studies with binary data. Am J Epidemiol. 2004;159(7):702–706.

16.

Ravndal

, Amundsen

EJ.

Mortality among drug users after discharge from inpatient treatment: an 8-year prospective study. Drug Alcohol Depend. 2010;108(1–2):65–69.

17.

Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality. Treatment Episode Data Set (TEDS): 2017. Admissions to and Discharges from Publicly-Funded Substance Use Treatment. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2019. https://www.samhsa.gov/data/sites/default/files/cbhsq-reports/TEDS-2017.pdf.

18.

Walley

, Doe-Simkins

, Quinn

, Pierce

, Xuan

, Ozonoff

Opioid overdose prevention with intranasal naloxone among people who take methadone. J Subst Abuse Treat. 2013;44(2):241–247.

19.

Doe-Simkins

, Bell

Opioid Overdose Prevention and Related Trauma: Incorporating Overdose Prevention, Response, and Experience into Substance Use Disorder Treatment. Chicago, IL: Illinois Cooccurring Center for Excellence at Heartland Health Outreach; 2014. https://prescribetoprevent.org/wp2015/wp-content/uploads/Incorporating-OD-into-SUD-Tx-12.141.pdf.

20.

Dayton

, Gicquelais

, Tobin

, . More than just availability: who has access and who administers take-home naloxone in Baltimore, MD. PLoS One. 2019;14(11):e0224686

21.

Binswanger

, Nowels

, Corsi

, . Return to drug use and overdose after release from prison: a qualitative study of risk and protective factors. Addict Sci Clin Pract. 2012;7:3.

22.

Mueller

, Koester

, Glanz

, Gardner

, Binswanger

IA.

Attitudes toward naloxone prescribing in clinical settings: a qualitative study of patients prescribed high dose opioids for chronic non-cancer pain. J Gen Intern Med. 2017;32(3):277–283.

23.

McCradden

, Vasileva

, Orchanian-Cheff

, Buchman

DZ.

Ambiguous identities of drugs and people: a scoping review of opioid-related stigma. Int J Drug Policy. 2019;74:205–215.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.05 MB